Regeneron (REGN) Tops Q3 EPS by 14c, Beats on Revenues
Get Alerts REGN Hot Sheet
Price: $906.54 -0.09%
EPS Growth %: +0.3%
Financial Fact:
Total other income (expense): 3.08M
Today's EPS Names:
NLY, CP, RUSHA, More
EPS Growth %: +0.3%
Financial Fact:
Total other income (expense): 3.08M
Today's EPS Names:
NLY, CP, RUSHA, More
Join SI Premium – FREE
Regeneron (NASDAQ: REGN) reported Q3 EPS of $3.99, $0.14 better than the analyst estimate of $3.85. Revenue for the quarter came in at $1.5 billion versus the consensus estimate of $1.46 billion.
- Third quarter 2017 EYLEA® (aflibercept) Injection U.S. net sales increased 12% to $953 million versus third quarter 2016
- Third quarter 2017 EYLEA global net sales(1) increased 15% to $1.52 billion versus third quarter 2016
- Third quarter 2017 GAAP net income per diluted share increased 46% to $3.32 versus third quarter 2016. Third quarter 2017 non-GAAP net income per diluted share increased 27% to $3.99 versus third quarter 2016.
- Phase 3 EYLEA PANORAMA study for the treatment of diabetic retinopathy is fully enrolled with U.S. regulatory submission expected in 2018
- Appellate court ordered a new trial and vacated permanent injunction in U.S. Praluent® patent case
For earnings history and earnings-related data on Regeneron (REGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regeneron Pharma (REGN) PT Raised to $1,030 at TD Cowen
- ATN International (ATNI) Misses Q1 EPS by 46c ; Offers Guidance
- First Bancorp. (FBNC) Misses Q1 EPS by 2c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!